SG11201908786VA - Substituted indoline derivatives as dengue viral replication inhibitors - Google Patents
Substituted indoline derivatives as dengue viral replication inhibitorsInfo
- Publication number
- SG11201908786VA SG11201908786VA SG11201908786VA SG11201908786VA SG 11201908786V A SG11201908786V A SG 11201908786VA SG 11201908786V A SG11201908786V A SG 11201908786VA SG 11201908786V A SG11201908786V A SG 11201908786VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- leuven
- dengue viral
- turnhoutseweg
- beerse
- Prior art date
Links
- 208000001490 Dengue Diseases 0.000 title abstract 5
- 206010012310 Dengue fever Diseases 0.000 title abstract 5
- 208000025729 dengue disease Diseases 0.000 title abstract 5
- 229940123627 Viral replication inhibitor Drugs 0.000 title abstract 2
- 125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 238000002360 preparation method Methods 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 abstract 1
- 150000002476 indolines Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I ill mu °million °nolo VII IE (10) International Publication Number WO 2018/178240 Al PCT (51) International Patent Classification: CO7D 403/12 (2006.01) A61P 31/14 (2006.01) A61K 31/41 (2006.01) (21) International Application Number: PCT/EP2018/058079 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164048.5 31 March 2017 (31.03.2017) EP (71) Applicants: JANSSEN PHARMACEUTICALS, INC. [US/US]; 1125 Trenton-Harbourton Road, Titusville, NJ New Jersey 08560 (US). KATHOLIEKE UNIVERSITEIT LEUVEN [BE/BE]; Waaistraat 6, bus 5105, 3000 Leuven (BE). (72) Inventors: KESTELEYN, Bart Rudolf Romanie; c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). BONFANTI, Jean-Francois; c/o Janssen-Cilag 1 rue Camille Desmoulins, TSA 91003, 92787 Issy-les-Moulin- eaux Cedex 9 (FR). COESEMANS, Erwin; c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). RABOISSON, Pierre Jean-Marie Bernard; c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). MARCHAND, Arnaud Didier M; c/o Cistim Leuven vzw Gaston Geenslaan 2, 3001 Leuven (Heverlee) (BE). BARDIOT, Dorothee Alice Marie-Eve; c/o Cistim Leu- ven vzw Gaston Geenslaan 2, 3001 Leuven (Heverlee) (BE). (74) Agent: GHEDIRA, Rim; Johnson & Johnson Patent Law Department, Turnhoutseweg 30, 2340 Beerse (BE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) CZ el (54) Title: SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS I N (57) : The present invention relates to substituted indoline derivatives, methods to prevent or treat dengue viral infections by 1-1 ----. using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the © compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral N infections. The invention also relates to processes for preparation of the compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17164048 | 2017-03-31 | ||
| PCT/EP2018/058079 WO2018178240A1 (en) | 2017-03-31 | 2018-03-29 | Substituted indoline derivatives as dengue viral replication inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908786VA true SG11201908786VA (en) | 2019-10-30 |
Family
ID=58464340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908786V SG11201908786VA (en) | 2017-03-31 | 2018-03-29 | Substituted indoline derivatives as dengue viral replication inhibitors |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US11083707B2 (en) |
| EP (1) | EP3601266B1 (en) |
| JP (1) | JP7203752B2 (en) |
| KR (1) | KR102530832B1 (en) |
| CN (1) | CN110461831B (en) |
| AR (1) | AR111314A1 (en) |
| AU (1) | AU2018246301B2 (en) |
| BR (1) | BR112019020175A2 (en) |
| CA (1) | CA3055867C (en) |
| CL (1) | CL2019002745A1 (en) |
| CO (1) | CO2019010295A2 (en) |
| CR (1) | CR20190446A (en) |
| DK (1) | DK3601266T3 (en) |
| EA (1) | EA039784B1 (en) |
| EC (1) | ECSP19070369A (en) |
| ES (1) | ES2884151T3 (en) |
| HR (1) | HRP20210942T1 (en) |
| HU (1) | HUE054678T2 (en) |
| IL (1) | IL269658B (en) |
| JO (1) | JOP20180025B1 (en) |
| LT (1) | LT3601266T (en) |
| MX (1) | MX386782B (en) |
| NI (1) | NI201900099A (en) |
| PE (1) | PE20191650A1 (en) |
| PH (1) | PH12019502201A1 (en) |
| SG (1) | SG11201908786VA (en) |
| SI (1) | SI3601266T1 (en) |
| TW (1) | TWI795393B (en) |
| UA (1) | UA126288C2 (en) |
| UY (1) | UY37645A (en) |
| WO (1) | WO2018178240A1 (en) |
| ZA (1) | ZA201906395B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (en) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JOP20160198B1 (en) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever |
| JO3633B1 (en) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | Single or binary substituted indole derivatives as inhibitors of viral replication of fennel fever |
| JP6931357B2 (en) | 2016-03-31 | 2021-09-01 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Substituted indoline derivative as a dengue virus replication inhibitor |
| DK3436435T3 (en) | 2016-03-31 | 2021-08-09 | Janssen Pharmaceuticals Inc | SUBSTITUTED CONTENT DERIVATIVES AS INHIBITORS OF DENGUEVIRUS REPLICATION |
| CR20180494A (en) | 2016-04-01 | 2019-01-29 | Janssen Pharmaceuticals Inc | DERIVATIVES OF INDOL SUBSTITUTES SUBSTITUTED AS INHIBITORS OF THE VIRIC REPLICATION OF DENGUE |
| JOP20170069B1 (en) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20180025B1 (en) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20180026A1 (en) * | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | Substituted indoline derivatives as dengue viral replication inhibitors |
| SI3630724T1 (en) | 2017-05-22 | 2021-08-31 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| JP7203764B2 (en) | 2017-05-22 | 2023-01-13 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Substituted Indoline Derivatives as Dengue Virus Replication Inhibitors |
| CN109485596A (en) * | 2018-12-19 | 2019-03-19 | 山东理工职业学院 | A kind of preparation method of the dengue virus inhibitor containing indoline |
| CN112159325B (en) * | 2020-10-10 | 2022-11-25 | 浙江工业大学 | Method for synthesizing 2-amino-3-nitrotoluene |
| WO2024252254A1 (en) * | 2023-06-05 | 2024-12-12 | Zydus Lifesciences Limited | Novel compounds to treat viral infections |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001520998A (en) | 1997-10-27 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | Morpholino-N-ethyl ester prodrug of indole sPLA2 inhibitor |
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| US20050074457A1 (en) | 2001-12-12 | 2005-04-07 | Adeela Kamal | Assays and implements for determining and modulating hsp90 binding activity |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| US20080262005A1 (en) | 2004-05-14 | 2008-10-23 | Neurocrine Biosciences, Inc. | Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto |
| KR20070098914A (en) | 2005-01-14 | 2007-10-05 | 제네랩스 테크놀로지스, 인코포레이티드 | Indole derivatives to treat viral infections |
| EP1853317A2 (en) | 2005-02-09 | 2007-11-14 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
| CN102056483A (en) | 2008-06-03 | 2011-05-11 | 西佳技术公司 | Small molecule inhibitors for the treatment or prevention of dengue virus infection |
| JP5559174B2 (en) | 2008-08-19 | 2014-07-23 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Cold sensation-menthol receptor antagonist |
| TWI453207B (en) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith |
| WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| US7948798B1 (en) | 2009-07-22 | 2011-05-24 | Marvell International Ltd. | Mixed multi-level cell and single level cell storage device |
| KR20120123678A (en) | 2010-01-15 | 2012-11-09 | 길리애드 사이언시즈, 인코포레이티드 | Inhibitors of flaviviridae viruses |
| EP2552211A4 (en) | 2010-03-26 | 2013-10-23 | Glaxo Group Ltd | Indazolyl-pyrimidines as kinase inhibitors |
| JP5716205B2 (en) | 2011-03-29 | 2015-05-13 | 学校法人日本大学 | Composition for inhibiting glucosidase activity and screening method thereof |
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| KR102290189B1 (en) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| ES2893251T3 (en) | 2014-01-31 | 2022-02-08 | Bristol Myers Squibb Co | Macrocycles with heterocyclic P2' groups as factor XIa inhibitors |
| HRP20190199T1 (en) | 2014-10-01 | 2019-04-05 | Janssen Pharmaceuticals, Inc. | MONO- OR DI-SUBSTITUTED INDOLA DERIVATIVES AS DENGA VIRUS REPLICATION INHIBITORS |
| HRP20190139T1 (en) | 2014-10-01 | 2019-03-22 | Janssen Pharmaceuticals, Inc. | MONO- OR DI-SUBSTITUTED INDOLES AS DENGA VIRUS REPLICATION INHIBITORS |
| NO2721243T3 (en) | 2014-10-01 | 2018-10-20 | ||
| PH12017501272B1 (en) | 2015-01-16 | 2023-01-11 | Janssen Pharmaceuticals Inc | Indole derivatives as dengue viral replication inhibitors |
| AR103680A1 (en) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | BACE1 SELECTIVE INHIBITORS |
| JOP20160086B1 (en) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JO3633B1 (en) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | Single or binary substituted indole derivatives as inhibitors of viral replication of fennel fever |
| JOP20160198B1 (en) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever |
| PT3370698T (en) | 2015-11-03 | 2022-03-02 | Zoetis Services Llc | Sol-gel polymer composites and uses thereof |
| JP6931357B2 (en) | 2016-03-31 | 2021-09-01 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Substituted indoline derivative as a dengue virus replication inhibitor |
| DK3436435T3 (en) | 2016-03-31 | 2021-08-09 | Janssen Pharmaceuticals Inc | SUBSTITUTED CONTENT DERIVATIVES AS INHIBITORS OF DENGUEVIRUS REPLICATION |
| EA036637B1 (en) | 2016-03-31 | 2020-12-02 | Такеда Фармасьютикал Компани Лимитед | Heterocyclic spiro compounds inhibiting monoacylglycerol lipase |
| JOP20170069B1 (en) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| PL3436457T3 (en) | 2016-04-01 | 2022-11-28 | Basf Se | Bicyclic compounds |
| SG11201808411RA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
| KR102731644B1 (en) | 2016-04-01 | 2024-11-19 | 카이트 파마 인코포레이티드 | Chimeric receptors and methods of use thereof |
| CN109069512B (en) | 2016-04-01 | 2022-06-14 | 西格诺药品有限公司 | Substituted aminopurine compounds, compositions thereof, and related methods of treatment |
| CR20180494A (en) | 2016-04-01 | 2019-01-29 | Janssen Pharmaceuticals Inc | DERIVATIVES OF INDOL SUBSTITUTES SUBSTITUTED AS INHIBITORS OF THE VIRIC REPLICATION OF DENGUE |
| PE20190201A1 (en) | 2016-04-01 | 2019-02-05 | Amgen Inc | FLT3 CHEMERICAL RECEPTORS AND METHODS OF USING THEM |
| JOP20180025B1 (en) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20180026A1 (en) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | Substituted indoline derivatives as dengue viral replication inhibitors |
| JP7203764B2 (en) | 2017-05-22 | 2023-01-13 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Substituted Indoline Derivatives as Dengue Virus Replication Inhibitors |
| SI3630724T1 (en) | 2017-05-22 | 2021-08-31 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
-
2018
- 2018-03-26 JO JOP/2018/0025A patent/JOP20180025B1/en active
- 2018-03-28 AR ARP180100776A patent/AR111314A1/en not_active Application Discontinuation
- 2018-03-29 EP EP18715612.0A patent/EP3601266B1/en active Active
- 2018-03-29 CR CR20190446A patent/CR20190446A/en unknown
- 2018-03-29 SG SG11201908786V patent/SG11201908786VA/en unknown
- 2018-03-29 LT LTEP18715612.0T patent/LT3601266T/en unknown
- 2018-03-29 UA UAA201910701A patent/UA126288C2/en unknown
- 2018-03-29 ES ES18715612T patent/ES2884151T3/en active Active
- 2018-03-29 US US16/493,768 patent/US11083707B2/en active Active
- 2018-03-29 JP JP2019553169A patent/JP7203752B2/en active Active
- 2018-03-29 DK DK18715612.0T patent/DK3601266T3/en active
- 2018-03-29 KR KR1020197031207A patent/KR102530832B1/en active Active
- 2018-03-29 PE PE2019001933A patent/PE20191650A1/en unknown
- 2018-03-29 HU HUE18715612A patent/HUE054678T2/en unknown
- 2018-03-29 MX MX2019011606A patent/MX386782B/en unknown
- 2018-03-29 CN CN201880022017.3A patent/CN110461831B/en active Active
- 2018-03-29 CA CA3055867A patent/CA3055867C/en active Active
- 2018-03-29 SI SI201830307T patent/SI3601266T1/en unknown
- 2018-03-29 BR BR112019020175-0A patent/BR112019020175A2/en active Search and Examination
- 2018-03-29 EA EA201992329A patent/EA039784B1/en unknown
- 2018-03-29 WO PCT/EP2018/058079 patent/WO2018178240A1/en not_active Application Discontinuation
- 2018-03-29 AU AU2018246301A patent/AU2018246301B2/en active Active
- 2018-03-29 TW TW107110872A patent/TWI795393B/en not_active IP Right Cessation
- 2018-03-29 HR HRP20210942TT patent/HRP20210942T1/en unknown
- 2018-04-02 UY UY0001037645A patent/UY37645A/en not_active Application Discontinuation
-
2019
- 2019-09-24 CO CONC2019/0010295A patent/CO2019010295A2/en unknown
- 2019-09-24 PH PH12019502201A patent/PH12019502201A1/en unknown
- 2019-09-25 IL IL269658A patent/IL269658B/en unknown
- 2019-09-26 CL CL2019002745A patent/CL2019002745A1/en unknown
- 2019-09-27 NI NI201900099A patent/NI201900099A/en unknown
- 2019-09-27 ZA ZA2019/06395A patent/ZA201906395B/en unknown
- 2019-09-27 EC ECSENADI201970369A patent/ECSP19070369A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer |